Arcadia Biosciences (RKDA) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $1.27 per share. This compares to loss of $2.64 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -38.58%. A quarter ago, it was expected that this agricultural biotechnology trait company would post a loss of $2.52 per share when it actually produced a loss of $1.78, delivering a surprise of 29.37%. Over the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other jurisdi ...

Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------|-------|---------------|-------|-------------------| | Assets | | June 30, 2024 | | December 31, 2023 | | Current assets: | | | | | | Cash and cash equivalents | $ | 5,504 | $ | 6,518 | | Short-term investments | | 2,604 | | 5,124 | | Accounts receivable and other r ...

This agricultural biotechnology trait company is expected to earn -$2.29 per share for the fiscal year ending December 2024, which represents a year-over-year change of 79.2%. Analysts have been steadily raising their estimates for Arcadia Biosciences. Over the past three months, the Zacks Consensus Estimate for the company has increased 54.3%. You can learn more about the Zacks Rank here >>> The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating syste ...

Arcadia Biosciences (RKDA) announced that it inked a deal with Above Food Corp. to sell its GoodWheat brand for $4 million. This move will allow Arcadia to scale its wheat IP by leveraging Above Food's vertically integrated farm-to-fork supply network. GoodWheat, which was launched in 2018, uses Arcadia's unique, patented and healthier wheat grain, which is naturally higher in fiber and protein. In June 2022, the company launched five variations of GoodWheat pasta, followed by six varieties of pancake mixes ...

The company reported an adjusted loss of $1.78 per share in the first quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of $2.52. This compares to a loss of $3.86 in the year-ago quarter. The company had recorded a valuation loss of $6 million related to March 2023 financing transaction in the first quarter of 2023. Including this, RKDA had reported a loss per share of $10.86 in the first quarter of 2023. Net sales were $1.26 million in the quarter under review, which marked a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other jurisdiction of incorporation or organization) 5950 Sherry Lane, Suite 215 Dallas, TX 75225 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Operator Thank you for standing by. My name is Parilla, and I will be your conference operator today. At this time, I would like to welcome everyone to the Arcadia Biosciences Q1 2024 Financial Results and Business Highlights Conference Call. All line ...

Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data and per share data) | | | | Three Months Ended March 31, | | | --- | --- | --- | --- | --- | | | | 2024 | | 2023 | | Revenues: | | | | | | Product | $ | 1,255 | $ | 1,232 | | Total revenues | | 1,255 | | 1,232 | | Operating expenses (income): | | | | | | Cost of revenues | | 820 | | 688 | | Research and development | | 272 | | 359 | | Loss (Gain) on sale of property and equipment | | 2 | | (19 ) | ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ET Company Participants T.J. Schaefer – Chief Financial Officer Stan Jacot – President and Chief Executive Officer Conference Call Participants Ben Klieve – Lake Street Capital Markets Dipesh Patel – H.C. Wainwright Operator Good afternoon and welcome to the Arcadia Biosciences Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Conference Call. At this time all participants are in a liste ...